BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

US Oncology, Inc. Research Affiliated Physicians to Present at 2011 American Society of Clinical Oncology Annual Meeting


5/26/2011 4:53:39 PM

THE WOODLANDS, Texas, May 26, 2011 /PRNewswire/ -- McKesson Specialty Care Solutions | US Oncology, a division of McKesson Corporation, announced today that four physicians affiliated with US Oncology Research and the United Network of US Oncology will give oral presentations at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) held June 3 - 7 at McCormick Place in Chicago.

ASCO is the world's leading professional organization representing physicians who care for people with cancer. More than 70 McKesson Specialty Care Solutions | US Oncology affiliated oncology experts have contributed to more than 60 studies being featured at this year's major medical meeting.

"US Oncology Research affiliated investigators are consistently on the cutting edge when it comes to the life-changing therapies of the future," said Nicholas Vogelzang, MD, oncologist at Comprehensive Cancer Centers of Nevada, co-chair of the Genitourinary Committee for US Oncology Research, and the communications chair of the 2011 ASCO Annual Meeting. "When it comes to advancing cancer care, these investigators are contributing in a major way. Take the MEK inhibitor study for example. The investigators understand molecular mechanisms, work with companies which have drugs targeting those mechanisms and use them to successfully treat patients in their practices. This is translational research at its best."

The four studies being presented orally at ASCO by US Oncology Research affiliated physicians are as follows:

Frankie Ann Holmes, MD, Texas Oncology


Sunday, June 5, 9:45 AM - 10:00 AM, Hall B1

Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy.



John Pippen, MD, FACP, Texas Oncology


Sunday, June 5, 4:30 PM - 4:45 PM, Hall B1

Randomized, phase III study of adjuvant doxorubicin + cyclophosphamide (AC) --> docetaxel (T) +/- capecitabine (X), in high-risk EBC: Exploratory Ki-67 analyses.



Joyce O'Shaughnessy, MD, Texas Oncology


Monday, June 6, 11:00 AM - 11:15 AM, Hall B1

A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).



Robert Jotte, MD, PhD, Rocky Mountain Cancer Centers


Tuesday, June 7, 8:00 AM - 8:15 AM, Arie Crown Theater

Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC).



"Studies such as these are leading to advances in treating cancer," said John Pippen, MD, FACP, Texas Oncology. "Our US Oncology clinical trials lead to approval of new drugs, better treatment combinations, and better prediction of whether a patient will benefit from a particular cancer treatment."

In addition to these oral presentations, Thomas E. Hutson, DO, PharmD, FACP, Texas Oncology, will be speaking during an education session on the management of unique subsets of patients with renal cell cancer. This session takes place on Sunday, June 5 in Hall D2 from 11:30 AM 12:45 PM.

US Oncology Research has a long history of bringing innovative and successful agents to market. To date, US Oncology Research has played a role in the development of 43 FDA approved cancer fighting therapies.

Other presentations that McKesson Specialty Care Solutions | US Oncology affiliated investigators are part of include:

Oral Presentations:

Thomas Cartwright, MD, Ocala Oncology Center


Saturday, June 4, 2:45 PM 3:00 PM, Hall D1

A multinational, randomized phase III study of bevacizumab (Bev) with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer (CC): Subgroup analyses from the AVANT trial.



Thomas E. Hutson, DO, PharmD, FACP, Texas Oncology


Saturday, June 4, 4:00 PM 4:15 PM, Arie Crown Theater

BRIM-2: An open-label, multicenter phase II study of RG7204 (PLX4032) in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.



Michael Teneriello, MD, FACOG, Texas Oncology


Saturday, June 4, 4:15 PM - 4:30 PM, E354a

OCEANS: A randomized, double-blinded, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC).



Jerome Goldschmidt, MD, Blue Ridge Cancer Care


Sunday, June 5, 10:00 AM - 10:15 AM, Hall D1

Final efficacy results from OAM4558g, a randomized Phase II study evaluating MetMAb or placebo in combination with Erlotinib in advanced NSCLC.



Daniel D. Von Hoff, MD, FACP, TGen, Scottsdale Healthcare, US Oncology Research


Sunday, June 5, 11:00 AM - 11:15 AM, Arie Crown Theater

Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86-9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer.



Thomas E. Hutson, DO, PharmD, FACP, Texas Oncology


Sunday, June 5, 11:50 AM - 12:10 PM, Hall D2

Management of Unique Subsets of Patients with Renal Cell Cancer.



Nicholas Vogelzang, MD, Comprehensive Cancer Centers of Nevada

Alexander Spira, MD, Virginia Cancer Specialists


Sunday, June 5, 12:00 PM - 12:15 PM, Arie Crown Theater

Cabozantinib (XL184) has activity in both soft tissue & bone: Results of a phase 2 randomized discontinuation trial (RDT) in patients (pts) w/ advanced solid tumors.



Thomas E. Hutson, DO, PharmD, FACP, Texas Oncology


Monday, June 6, 8:00 AM - 8:15 AM, Hall D2

Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial.



Jeff Sharman, MD, Willamette Valley Cancer Institute and Research Center

Donald Richards, MD, PhD, Texas Oncology


Monday, June 6, 9:30 AM - 12:30 PM, Arie Crown Theater

Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study.



Alexander Spira, MD, Virginia Cancer Specialists

Nicholas Vogelzang, MD, Comprehensive Cancer Centers of Nevada


Monday, June 6, 1:15 PM - 1:30 PM, Hall D1

Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.



Poster Discussions:

Daniel D. Von Hoff, MD, FACP, TGen, Scottsdale Healthcare, US Oncology Research


Poster #23

Saturday, June 4, 8:00 AM 12:00 PM, S403


Discussion

12:00 PM 1:00 PM, S406

Phase I clinical trial of VTX-2337, a selective toll-like receptor 8 (TLR8) agonist, in patients with advanced solid tumors.




Daniel D. Von Hoff, MD, FACP, TGen, Scottsdale Healthcare, US Oncology Research


Poster #5

Saturday, June 4, 2:00 PM - 6:00 PM, S403


Discussion

5:00 PM - 6:00 PM, S406

Phase I study of the multikinase prodrug SF1126 in solid tumors and B-cell malignancies.




Guru Sonpavde, MD, Texas Oncology

Mark Fleming, MD, Virginia Oncology Associates

Thomas E. Hutson, DO, PharmD, FACP, Texas Oncology


Poster #8

Saturday, June 4, 2:00 PM - 6:00 PM, E450a


Discussion

5:00 PM - 6:00 PM, Hall D

A randomized, double-blind phase II trial of docetaxel plus prednisone (DP) combined with either AT-101 or placebo for the first-line therapy of metastatic castration-resistant prostate cancer (CRPC).




Thomas E. Hutson, DO, PharmD, FACP, Texas Oncology


Poster #17

Saturday, June 4, 2:00 PM - 6:00 PM, S103


Discussion

5:00 PM - 6:00 PM, S100bc

Circulating protein biomarkers of sunitinib and interferon efficacy in treatment naive patients with metastatic renal cell carcinoma.




Carlos Becerra, MD, Texas Oncology


Poster #14

Monday, June 6, 8:00 AM - 12:00 PM, E450b


Discussion

11:30 AM - 12:30 PM, Hall D1

Phase II trial of figitumumab in patients with refractory, metastatic colorectal cancer (mCRC).




Donald Richards, MD, PhD, Texas Oncology

Darren M Kocs, MD, Texas Oncology

Alexander Spira, MD, Virginia Cancer Specialists

David McCollum, MD, Texas Oncology

Kristi Boehm, Feng Zhan, PhD, Lina Asmar, PhD, US Oncology Research


Poster #8

Monday, June 6, 2:00 PM - 6:00 PM, E450b


Discussion

5:00 PM - 6:00 PM, Hall D1

Results of docetaxel plus oxaliplatin (DOCOX) +/- cetuximab in patients with metastatic gastric and/or gastroesophagel junction adenocarcinoma; results of a randomized phase II study.




Donald Richards, MD, PhD, Texas Oncology


Poster #11

Monday, June 6, 2:00 PM - 6:00 PM, E450b


Discussion

5:00 PM - 6:00 PM, Hall D1

Randomized phase II study (GATE study) of docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer.




Guru Sonpavde, MD, Texas Oncology

Nicholas Vogelzang, MD, Comprehensive Cancer Centers of Nevada

Peter Rosen, MD, Roy & Patricia Disney Cancer Research Center

Alexander Spira, MD, Virginia Cancer Specialists


Poster #22

Tuesday, June 7, 8:00 AM - 12:00 PM, E450b


Discussion

11:30 AM - 12:30 PM, E354a

Clinical outcome of single agent volasertib (BI 6727) as second-line treatment of patients (pts) with advanced or metastatic urothelial cancer (UC).



Posters:

Joyce O'Shaughnessy, MD, Texas Oncology

Thomas Cartwright, MD, Ocala Oncology Center


Poster #21C

Saturday, June 4, 8:00 AM - 12:00 PM, Hall A

Effect of dose modification on the efficacy of capecitabine: Data from six randomized, phase III trials in patients with colorectal or breast cancer.




Joe Stephenson, MD, Cancer Centers of t

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES